Four Approved Frontline Treatments Benefit Patients with Chronic Myeloid Leukemia Real-World Effectiveness of Dasatinib Versus Imatinib in Newly What if I miss a dose of my TKI / Missed a TKI dose / CML / Chronic Myeloid Leukemia
Dr Lu talks to ecancertv at EHA 2016 about ponatinib, whose exact resistance mechanisms are not yet fully understood. Ponatinib Day one of the Chronic Myeloid Leukemia fight. 1st Sprycel Dose The purpose of this clinical research study is to compare the confirmed complete cytogenetic response of dasatinib with that of imatinib within 12 months after
Dasatinib or imatinib in newly diagnosed chronic-phase chronic Visit for more Dr Slayton (University of Florida, Gainsville, USA) talks to ecancertv at ASCO 2015, about the Stephen O'Brien, PhD, MBChB, FRCP, FRCPath from Newcastle University, Newcastle, UK, provides an overview of his talk on
Relapsed CML: Mutation Testing and Therapy Choices Tyrosine Kinase Inhibitors (TKIs) - Imatinib (Gleevec) - Pharmacology - CML and ALL
Comparing dasatinib-blinatumomab vs ponatinib-blinatumomab in newly diagnosed Ph+ B-ALL Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses the use of reduced-intensity
Debate: Chronic-Phase CML Patient Develops a T315I Mutation - Experimental Therapy In this segment, panelists discuss treatment with ponatinib and omacetaxine mepesuccinate for patients with chronic myeloid
Treatment with dasatinib, a highly potent BCR-ABL kinase inhibitor, has resulted in high rates of complete cytogenetic response and Tyrosine Kinase Inhibitors (TKIs) | Imatinib (Gleevec) | Philadelphia Chromosome | CML and ALL Animated Mnemonics
Filmed on location in New York during the Great Debates & Updates in Hematologic Malignancies 2015, this webcast is part of a Updates in CML: recent trials and novel agents Management of Thrombosis Risk with Ponatinib and other TKIs for CML?
Created using Powtoon -- Free sign up at -- Create animated videos and animated Michael J. Mauro, MD from the Memorial Sloan Kettering Cancer Center, New York, NY discusses his talk on predictors of Dasatinib-blinatumomab for ALL
Dr. Vivian Oehler from Fred Hutch and Seattle Cancer Care Alliance in Seattle, WA, discusses updates in Chronic Myelogenous Gleevec: Mechanism of Action What are the predictors of ponatinib treatment response?
DESTINY: achieving TFR by de-escalating therapy in CML SPIRIT2 trial on dasatinib for AML - safety and side effect management Asciminib plus dasatinib for the treatment of Ph+ B-ALL: insights from a Phase I trial
Robin Foà, MD, Sapienza University of Rome, Rome, Italy, discusses a dasatinib-blinatumomab combination for the frontline Comparing Frontline Therapies for the Treatment of Chronic Myeloid Leukemia
Highlights of promising clinical trials of novel agents for chronic myeloid leukemia (CML) are overviewed here by Susanne At the 20th Congress of the European Hematology Association (EHA), Giuseppe Saglio, MD, of the University of Turin, Turin, Italy,
Treatment Selection for Resistant or Intolerant Chronic Myeloid Leukemia Michael J. Mauro, MD, a hematologist at Memorial Sloan Kettering Cancer Center, discusses how 4 FDA-approved frontline Dasatinib Scientific Commercial
Dr Katerina Machova Polakova talks to ecancertv at EHA 2016 about single nucleotide polymorphisms (SNPs) associated with IACH Journal Club Dasatinib–Blinatumomab for Ph Positive Acute Lymphoblastic Leukemia in Adul Speakers: Dr. Robin Foà and
Dr Pui talks to ecancer at ASH 2019 about his study to determine whether dasatinib given at 80 mg/m2 is more effective than Richard Clark, MA, MD, MRCP, FRCPath, of the Royal Liverpool University Hospital, Liverpool, UK, presented the final results of Coping with Side Effects
Final 5-Year Study Results of DASISION: The Dasatinib Versus Results of the Phase III DASISION trial and the future of CML treatment
Michael Mauro, MD, of Memorial Sloan Kettering Cancer Center, New York City, NY, discusses the outcome of the DASFREE trial Elizabeth Rajasingh of KEI talks about the efforts of the US government to pressure India, in order to block a compulsory license Dasatinib prednisone induction prior to transplant for Ph+ ALL
Successful TFR in DASFREE: dasatinib for R/R CML Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. J India-US dispute over patents on dasatinib, a drug to treat leukemia
Final analysis of the GIMEMA LAL2116 (D-ALBA) trial: dasatinib + blinatumomab in Ph+ B-ALL Reduced-intensity induction + dasatinib vs hyperCVAD + TKIs in PH+ ALL
Giuseppe Saglio, MD of the University of Turin, Turin, Italy discusses the pros and cons of chronic myeloid leukemia (CML) Second-generation tyrosine kinase inhibitors for chronic myeloid leukemia Sabina Chiaretti, MD, PhD, University of Rome, Rome, Italy, discusses the final follow-up of the GIMEMA LAL2116 (D-ALBA) trial
IACH Journal Club: Dasatinib–Blinatumomab for Ph Positive Acute Lymphoblastic Leukemia in Adul Kris Griffin speaks about his experience changing from imatinib to dasatinib Dr Shuhong Shen speaks to ecancer at the ASH 2019 meeting in Orlando about updated results from a study treating paediatric
Upfront Treatment in Chronic Myeloid Leukemia (CML) Discontinuing treatment and predicting relapse in CML
This study found that dasatinib at a dosage of 80 mg/m2 per day was more effective than imatinib mesylate at a dosage of 300 mg/m2 per day in Joaquin Martinez-Lopez, MD, PhD, of the Universidad Complutense de Madrid, Madrid, Spain, discusses a Phase I trial Chronic Myeloid Leukemia (CML) patient, Diane, shares helpful tips for coping with side effects. For more information on CML,
Neal Shore, MD, describes how to select the best candidates for dasatinib. Panelists discuss approaches to selecting a first-line tyrosine kinase inhibitor for initial therapy in patients with newly diagnosed
Dasatinib plus nivolumab in patients with previously treated CML The current treatment landscape of CML is at a very exciting time. Here, Timothy Hughes, MD, of the Royal Adelaide Hospital,
Marc Schwartz, MD, University of Colorado, Aurora, CO, discusses institutional outcomes of patients with Philadelphia Chronic myeloid leukemia (CML) stem cells are thought to evade treatment through disruption in the environment within the bone Sabina Chiaretti, MD, PhD, University of Rome, Rome, Italy, shares insights into the GIMEMA ALL2820 trial (NCT04722848),
The current standard of care in CML and insights into the use of first- and second-generation TKIs Final results of the BFORE trial: bosutinib vs imatinib in CP-CML
The importance of achieving early molecular response in CML Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Dr. Neil Shah discusses the efficacy and safety considerations of dasatinib therapy. Join our online communities to begin
Dasatinib vs imatinib for paediatric Ph+ALL Hagop Kantarjian, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the findings of an analysis of Earn CME for related activities: In this presentation from the 2019 Great Debates & Updates in
Michael Deininger, MD, PhD, The Medical College of Wisconsin, Milwaukee, WI, gives an overview of the final results of the Dasatinib in the Second-Line Setting What are the efficacy and safety considerations of dasatinib therapy?
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic For more information, visit CancerQuest at The kinase inhibitor, Gleevec, Javier A. Pinilla-Ibarz, MD, PhD, comments on how to characterize the 64-year-old patient's response to imatinib, the importance
Elisabetta Abruzzese, MD, PhD, S. Eugenio University Hospital, Rome, Italy, discusses the implications and challenges of having Ponatinib in chronic-phase CML patients with prior second generation TKI exposure
Mutations associated with imatinib response in CML Jorge E. Cortes, MD, deputy chief and a professor of medicine in the Department of Leukemia at The University of Texas MD
Dasatinib vs. imatinib in patients with chronic myeloid leukemia in first day of Sprycel #chronicmyeloidleukemia #leukemia. Treating the Newly Diagnosed Patient With Chronic Myeloid Leukemia
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Jorge Cortes, MD, Augusta University, Augusta, GA, summarizes the design and updated findings of the BFORE trial Imatinib, Nilotinib, dasatinib mechanism of action
Initial results showed that dasatinib had superior efficacy over imatinib during the first year of therapy, including significantly higher rates of complete Effects of dasatinib on xenograft lung tumour models with YES1 overexpression Modelling ponatinib resistance in BCR-ABL1 cell lines
Dasatinib vs imatinib in the treatment of paediatric ALL Dasatinib, administered once daily, as compared with imatinib, administered once daily, induced significantly higher and faster rates of complete cytogenetic
Early response with dasatinib or imatinib in chronic myeloid CML: Considering Second-Generation TKIs The panelists, Jorge Cortes, MD; Kevin Kelly, MD, PhD; David Snyder, MD, FACP; Harry Erba, MD, PhD; and Javier Pinilla-Ibarz,
In this study, patients who switched to dasatinib at 3 months had a significantly higher MMR rate at 12 months than patients who remained on Giuseppe Saglio, MD of the University of Turin, Turin, Italy provides an overview of the results of the Phase III trial of DASISION in Harry P. Erba, MD; Michael Mauro, MD; and Jorge E. Cortes, MD, evaluate the significance of the second-generation tyrosine
Pros and cons of CML first-line therapy CML during pregnancy: implications and considerations for treatment
Dasatinib plus intensive chemo versus stem cell transplant for Philadelphia chromosome positive ALL 5-year update of BFORE: bosutinib vs imatinib in CML NCT00481247 | A Phase III Study of Dasatinib vs Imatinib in Patients
Giuseppe Saglio, MD, University of Turin, Turin, Italy, shares some insights into the current standard of care in chronic myeloid Dasatinib was associated with a higher percentage of patients achieving BCR-ABL transcript levels ≤10% compared with imatinib (84% vs 64%; P < .0001). Similarly In the DASISION trial, dasatinib demonstrated an increased MMR rate and faster response time compared with imatinib across all Hasford risk categories,21 but
Marlise Luskin, MD, MSCE, Dana-Farber Cancer Institute, Boston, MA, discusses a Phase I dose-escalation trial (NCT03595917) Dr Garmendia speaks with ecancer at AACR 2018 about patient derived xenografts (PDX) of lung tumours with high levels of
ICAHO20 ASCO Direct™ Highlights - Dr. Vivian Oehler - CML & MPN in 2020 If you miss a dose of your TKI, here is what to do, depending on the TKI you take. 0:00 Start 0:17 Gleevec 0:35 Sprycel 0:47